KEYTRUDA 25 mg/mL concentrate for solution for infusion, S095029/Sym025
CL1-95029-002
Phase 2 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, S095029/Sym025 for MSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- MSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active